In this exclusive interview with Sir Michael Rawlins, the Chairman of NICE, Fintan Walton discusses the financial issues facing pharmaceutical and biotech companies throughout the drug discovery and development process. Following several comments made by Sir Michael Rawlins in the UK national pr...
(less)
In an interview with Ann Salter, Fintan Walton, CEO, PharmaVentures, looks back at the successful creation of PharmaVentures Business Review and discusses its growth and development since its launch in May 2006. He highlights the aims and strategy surrounding the formation of PharmaTelevision an...
(less)
Is the Pfizer and Wyeth deal a good move? Does this provide opportunities for other big pharma in 2009? Tibor Papp and Kevin Bottomley of PharmaVentures answer these questions and more in this special edition of the PharmaVentures Business Review.
(less)
In this exclusive interview, Fintan Walton talks to Graham Brazier, Vice President and Head of Business Development at Bristol-Myers Squibb (BMS), about the world of big pharma business development and the process of in-licensing. Because the interview took place at the AusBiotech 2007 conferenc...
(less)
In this informative panel discussion, Fintan Walton talks with 3 members of PharmaVentures’ deal advisory team about Royalty Rates, particularly the valuation of deals in the pharmaceutical and biotech industry, and the challenge to find information about Royalty Rates not generally available in...
(less)
What are the new out-licensing practices of large pharma? How can biotechs capitalise on these? Having the right business models and practices that match the new opportunities is key to success. The leading companies of our industry are acutely aware of this need and have implemented new ways of ...
(less)
Fintan Walton talks to Jeremy Curnock Cook, Bioscience Managers, John Wilkinson, Reed Smith, and Jim McCarthy, PharmaVentures, about the state of the industry in 2006 and what’s likely to happen in 2007. The panellists start by discussing how 2006 saw significant funds transferring from pharma t...
(less)
Dr Mark Ashton talks to Fintan Walton about Evotec’s evolving business model, which is based on both contract research services and proprietary research in the CNS field. In particular, they discuss Evotec's successful alliance history with Roche that dates back to 2001. Dr Ashton talks in depth...
(less)
Safe Search Filter is ON. Truveo understands that some content may not be appropriate for all users. We provide a Safe Search Filter so that you can choose the content best suited to your personal interest. Turning OFF the Safe Search Filter may display content that is only suitable for viewers over 18 years of age. Click the button below if you are over 18 and would like to turn OFF the Safe Search Filter.